Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Wanja Kassuhn"'
Autor:
Wanja Kassuhn, Pedro R. Cutillas, Mirjana Kessler, Jalid Sehouli, Elena I. Braicu, Nils Blüthgen, Hagen Kulbe
Publikováno v:
Cancers, Vol 15, Iss 12, p 3155 (2023)
Background: Tumour heterogeneity in high-grade serous ovarian cancer (HGSOC) is a proposed cause of acquired resistance to treatment and high rates of relapse. Among the four distinct molecular subtypes of HGSOC, the mesenchymal subtype (MES) has bee
Externí odkaz:
https://doaj.org/article/68c502e5937148b0a174b370f41e1878
Autor:
Wanja Kassuhn, Oliver Klein, Silvia Darb-Esfahani, Hedwig Lammert, Sylwia Handzik, Eliane T. Taube, Wolfgang D. Schmitt, Carlotta Keunecke, David Horst, Felix Dreher, Joshy George, David D. Bowtell, Oliver Dorigo, Michael Hummel, Jalid Sehouli, Nils Blüthgen, Hagen Kulbe, Elena I. Braicu
Publikováno v:
Cancers, Vol 13, Iss 7, p 1512 (2021)
Despite the correlation of clinical outcome and molecular subtypes of high-grade serous ovarian cancer (HGSOC), contemporary gene expression signatures have not been implemented in clinical practice to stratify patients for targeted therapy. Hence, w
Externí odkaz:
https://doaj.org/article/ebedade1c03c46f5ac65ecf184ca3e25
Autor:
Hagen Kulbe, Oliver Klein, Zhiyang Wu, Eliane T. Taube, Wanja Kassuhn, David Horst, Silvia Darb-Esfahani, Paul Jank, Salem Abobaker, Frauke Ringel, Andreas du Bois, Florian Heitz, Jalid Sehouli, Elena I. Braicu
Publikováno v:
Cancers, Vol 12, Iss 8, p 2000 (2020)
With regard to relapse and survival, early-stage high-grade serous ovarian (HGSOC) patients comprise a heterogeneous group and there is no clear consensus on first-line treatment. Currently, no prognostic markers are available for risk assessment by
Externí odkaz:
https://doaj.org/article/4da7c9a093d140a789c5bdc4aec6fbd3
Autor:
Kulbe, Wanja Kassuhn, Pedro R. Cutillas, Mirjana Kessler, Jalid Sehouli, Elena I. Braicu, Nils Blüthgen, Hagen
Publikováno v:
Cancers; Volume 15; Issue 12; Pages: 3155
Background: Tumour heterogeneity in high-grade serous ovarian cancer (HGSOC) is a proposed cause of acquired resistance to treatment and high rates of relapse. Among the four distinct molecular subtypes of HGSOC, the mesenchymal subtype (MES) has bee
Autor:
Carlotta Keunecke, Hagen Kulbe, Felix Dreher, Eliane T. Taube, Radoslav Chekerov, David Horst, Michael Hummel, Thomas Kessler, Klaus Pietzner, Wanja Kassuhn, Florian Heitz, Mustafa Z. Muallem, Susan M. Lang, Ignace Vergote, Oliver Dorigo, Hedwig Lammert, Andreas du Bois, Tim Angelotti, Christina Fotopoulou, Jalid Sehouli, Elena I. Braicu
Publikováno v:
Gynecologic Oncology. 166:334-343
High-grade serous ovarian cancer (HGSOC) is the most common subtype of ovarian cancer and is associated with high mortality rates. Surgical outcome is one of the most important prognostic factors. There are no valid biomarkers to identify which patie
Publikováno v:
PSB
CLIP-Seq protocols such as PAR-CLIP, HITS-CLIP or iCLIP allow a genome-wide analysis of protein-RNA interactions. For the processing of the resulting short read data, various tools are utilized. Some of these tools were specifically developed for CLI